FDA Clears Dexcom Stelo as First OTC CGM for Children 2 and Older Without Insulin

The clearance expands the adult OTC indication granted in March 2024. Stelo samples interstitial glucose every 15 minutes for up to 15 days per sensor and displays trends but supplies no hypoglycemia alarms. FDA reviewed mild skin irritation and infection rates from prior adult and limited pediatric data; no randomized trials in children under 18 were required for this 510(k) pathway. The decision aligns with CDC data showing rising type 2 diabetes and prediabetes prevalence in U.S. youth, yet the device is explicitly not indicated for insulin users or those with severe hypoglycemia risk.

Access without prescription lowers immediate barriers for families managing lifestyle-driven glucose excursions, potentially shifting monitoring costs from insurance-covered prescription CGMs to out-of-pocket purchases estimated at $100–150 monthly. Daily routines change because parents can apply the waterproof sensor at home and review patterns without clinic visits, though the FDA requires continued provider oversight for any medication or diet changes. This mirrors earlier OTC switches such as emergency contraception, where convenience gains coexist with risks of underuse of professional care.

Observational claims of lifestyle insight rest on adult accuracy data extrapolated downward; no large-scale pediatric outcome studies yet demonstrate reduced progression to diabetes or improved HbA1c. Next required evidence includes post-market surveillance of real-world adherence, skin complications in active children, and whether routine use alters eating-disorder risk in adolescents.

Longer-term questions center on equity: uninsured families may still face sensor replacement costs, and integration with school or camp settings remains untested.